TGF-β and atherosclerosis in man

Cardiovascular Research

Volumn 74, Issue 2, 2007, Pages 213-222

  Grainger, David J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Autoimmunity; Blood vessel; Inflammation; T cell

Indexed keywords

BINDING PROTEIN; CYTOKINE; LIGAND; RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CELL TYPE; CHRONIC INFLAMMATION; CYTOKINE RELEASE; HUMAN; IMMUNOREGULATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; T LYMPHOCYTE;

ATHEROSCLEROSIS; AUTOIMMUNITY; HUMANS; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA;

EID: 34047156083     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2007.02.022     Document Type: Review

References (102)

1. Weissberg P.L., and Rudd J.H.F. Atherosclerotic biology and epidemiology of disease. In: Topol E.J. (Ed). Textbook of cardiovascular medicine (2002), Lippincott Williams & Wilkins, Philidelphia 3-14
2. Falk E. Why do plaques rupture?. Circulation 86 (1992) III30-III42
3. Ross R. Atherosclerosis: a question of endothelial integrity and growth control of smooth muscle. Harvey Lect 77 (1981) 161-182
4. Weissberg P.L., Clesham G.J., and Bennett M.R. Is vascular smooth muscle cell proliferation beneficial?. Lancet 347 (1996) 305-307
5. Hoofnagle M.H., Thomas J.A., Wamhoff B.R., and Owens G.K. Origin of neointimal smooth muscle: we've come full circle. Arterioscler Thromb Vasc Biol 26 (2006) 2579-2581
6. Hansson G.K., Libby P., Schonbeck U., and Yan Z.Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 91 (2002) 281-291
7. Tedgui A., and Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86 (2006) 515-581
8. Grainger D.J., and Metcalfe J.C. A pivotal role for TGF-beta in atherogenesis?. Biol Rev Camb Philos Soc 70 (1995) 571-596
9. Hansson G.K., and Robertson A.K. TGF-beta in atherosclerosis. Arterioscler Thromb Vasc Biol 24 (2004) E137 [author reply E-8]
10. Mallat Z., and Tedgui A. The role of transforming growth factor beta in atherosclerosis: novel insights and future perspectives. Curr Opin Lipidol 13 (2002) 523-529
11. Singh N.N., and Ramji D.P. The role of transforming growth factor-beta in atherosclerosis. Cytokine Growth Factor Rev (2006)
12. Ignotz R.A., Endo T., and Massague J. Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-beta. J Biol Chem 262 (1987) 6443-6446
13. Penttinen R.P., Kobayashi S., and Bornstein P. Transforming growth factor beta increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability. Proc Natl Acad Sci U S A 85 (1988) 1105-1108
14. Grainger D.J., Kemp P.R., Witchell C.M., Weissberg P.L., and Metcalfe J.C. Transforming growth factor beta decreases the rate of proliferation of rat vascular smooth muscle cells by extending the G2 phase of the cell cycle and delays the rise in cyclic AMP before entry into M phase. Biochem J 299 Pt 1 (1994) 227-235
15. Owens G.K., Geisterfer A.A., Yang Y.W., and Komoriya A. Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells. J Cell Biol 107 (1988) 771-780
16. Bjorkerud S. Effects of transforming growth factor-beta 1 on human arterial smooth muscle cells in vitro. Arterioscler Thromb 11 (1991) 892-902
17. Gamble J.R., Khew-Goodall Y., and Vadas M.A. Transforming growth factor-beta inhibits E-selectin expression on human endothelial cells. J Immunol 150 (1993) 4494-4503
18. Argmann C.A., Van Den Diepstraten C.H., Sawyez C.G., Edwards J.Y., Hegele R.A., Wolfe B.M., et al. Transforming growth factor-beta1 inhibits macrophage cholesteryl ester accumulation induced by native and oxidized VLDL remnants. Arterioscler Thromb Vasc Biol 21 (2001) 2011-2018
19. Bobik A. Transforming growth factor-betas and vascular disorders. Arterioscler Thromb Vasc Biol 26 (2006) 1712-1720
20. Grainger D.J. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 24 (2004) 399-404
21. Grainger D.J., Mosedale D.E., Metcalfe J.C., and Bottinger E.P. Dietary fat and reduced levels of TGFbeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions. J Cell Sci 113 Pt 13 (2000) 2355-2361
22. Mallat Z., Gojova A., Marchiol-Fournigault C., Esposito B., Kamate C., Merval R., et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 89 (2001) 930-934
23. Grainger D.J., Mosedale D.E., and Metcalfe J.C. TGF-beta in blood: a complex problem. Cytokine Growth Factor Rev 11 (2000) 133-145
24. Grainger D.J., Kemp P.R., Metcalfe J.C., Liu A.C., Lawn R.M., Williams N.R., et al. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat Med 1 (1995) 74-79
25. Erren M., Reinecke H., Junker R., Fobker M., Schulte H., Schurek J.O., et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 19 (1999) 2355-2363
26. Os I., Djurovic S., Seljeflot I., and Berg K. Transforming growth factor (TGF)-beta1 inversely related to vascular cell adhesion molecule-1 in postmenopausal women with coronary artery disease. A possible mechanism for the putative cardioprotective role of TGF-beta1?. J Intern Med 251 (2002) 223-227
27. Wang X.L., Liu S.X., and Wilcken D.E. Circulating transforming growth factor beta 1 and coronary artery disease. Cardiovasc Res 34 (1997) 404-410
28. Jiang X., Zeng H.S., Guo Y., Zhou Z.B., Tang B.S., and Li F.K. The expression of matrix metalloproteinases-9, transforming growth factor-beta1 and transforming growth factor-beta receptor I in human atherosclerotic plaque and their relationship with plaque stability. Chin Med J (Engl) 117 (2004) 1825-1829
29. Borkowski P., Robinson M.J., Kusiak J.W., Borkowski A., Brathwaite C., and Mergner W.J. Studies on TGF-beta 1 gene expression in the intima of the human aorta in regions with high and low probability of developing atherosclerotic lesions. Mod Pathol 8 (1995) 478-482
30. Grainger D.J., Metcalfe J.C., Grace A.A., and Mosedale D.E. Transforming growth factor-beta dynamically regulates vascular smooth muscle differentiation in vivo. J Cell Sci 111 Pt 19 (1998) 2977-2988
31. Reckless J., Rubin E.M., Verstuyft J.B., Metcalfe J.C., and Grainger D.J. A common phenotype associated with atherogenesis in diverse mouse models of vascular lipid lesions. J Vasc Res 38 (2001) 256-265
32. Bobik A., Agrotis A., Kanellakis P., Dilley R., Krushinsky A., Smirnov V., et al. Distinct patterns of transforming growth factor-beta isoform and receptor expression in human atherosclerotic lesions. Colocalization implicates TGF-beta in fibrofatty lesion development. Circulation 99 (1999) 2883-2891
33. Piao M., and Tokunaga O. Significant expression of endoglin (CD105), TGFbeta-1 and TGFbeta R-2 in the atherosclerotic aorta: an immunohistological study. J Atheroscler Thromb 13 (2006) 82-89
34. Panutsopulos D., Papalambros E., Sigala F., Zafiropoulos A., Arvanitis D.L., and Spandidos D.A. Protein and mRNA expression levels of VEGF-A and TGF-beta1 in different types of human coronary atherosclerotic lesions. Int J Mol Med 15 (2005) 603-610
35. Takayama T., Kaneko K., Morelli A.E., Li W., Tahara H., and Thomson A.W. Retroviral delivery of transforming growth factor-beta1 to myeloid dendritic cells: inhibition of T-cell priming ability and influence on allograft survival. Transplantation 74 (2002) 112-119
36. Kempf K., Haltern G., Futh R., Herder C., Muller-Scholze S., Gulker H., et al. Increased TNF-alpha and decreased TGF-beta expression in peripheral blood leukocytes after acute myocardial infarction. Horm Metab Res 38 (2006) 346-351
37. Grainger D.J., Heathcote K., Chiano M., Snieder H., Kemp P.R., Metcalfe J.C., et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 8 (1999) 93-97
38. Silverman E.S., Palmer L.J., Subramaniam V., Hallock A., Mathew S., Vallone J., et al. Transforming growth factor-beta1 promoter polymorphism C-509T is associated with asthma. Am J Respir Crit Care Med 169 (2004) 214-219
39. Luedecking E.K., DeKosky S.T., Mehdi H., Ganguli M., and Kamboh M.I. Analysis of genetic polymorphisms in the transforming growth factor-beta1 gene and the risk of Alzheimer's disease. Hum Genet 106 (2000) 565-569
40. Awad M.R., El-Gamel A., Hasleton P., Turner D.M., Sinnott P.J., and Hutchinson I.V. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 66 (1998) 1014-1020
41. Suthanthiran M., Li B., Song J.O., Ding R., Sharma V.K., Schwartz J.E., et al. Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci U S A 97 (2000) 3479-3484
42. Yamada Y., Miyauchi A., Goto J., Takagi Y., Okuizumi H., Kanematsu M., et al. Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J Bone Miner Res 13 (1998) 1569-1576
43. Yokota M., Ichihara S., Lin T.L., Nakashima N., and Yamada Y. Association of a T29->C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 101 (2000) 2783-2787
44. Cambien F., Ricard S., Troesch A., Mallet C., Generenaz L., Evans A., et al. Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study. Hypertension 28 (1996) 881-887
45. Syrris P., Carter N.D., Metcalfe J.C., Kemp P.R., Grainger D.J., Kaski J.C., et al. Transforming growth factor-beta1 gene polymorphisms and coronary artery disease. Clin Sci (Lond) 95 (1998) 659-667
46. Wang X.L., Sim A.S., and Wilcken D.E. A common polymorphism of the transforming growth factor-beta1 gene and coronary artery disease. Clin Sci (Lond) 95 (1998) 745-746
47. Crivello A., Giacalone A., Scola L., Forte G.I., Nuzzo D., Giacconi R., et al. Frequency of polymorphisms of signal peptide of TGF-beta1 and-1082G/A SNP at the promoter region of Il-10 gene in patients with carotid stenosis. Ann N Y Acad Sci 1067 (2006) 288-293
48. Koch W., Hoppmann P., Mueller J.C., Schomig A., and Kastrati A. Association of transforming growth factor-beta1 gene polymorphisms with myocardial infarction in patients with angiographically proven coronary heart disease. Arterioscler Thromb Vasc Biol 26 (2006) 1114-1119
49. Sie M.P., Uitterlinden A.G., Bos M.J., Arp P.P., Breteler M.M., Koudstaal P.J., et al. TGF-beta 1 polymorphisms and risk of myocardial infarction and stroke: the Rotterdam Study. Stroke 37 (2006) 2667-2671
50. Kim Y., and Lee C. The gene encoding transforming growth factor beta 1 confers risk of ischemic stroke and vascular dementia. Stroke 37 (2006) 2843-2845
51. Oda K., Tanaka N., Arai T., Araki J., Song Y., Zhang L., et al. Polymorphisms in pro- and anti-inflammatory cytokine genes and susceptibility to atherosclerosis: a pathological study of 1503 consecutive autopsy cases. Hum Mol Genet (2007)
52. Tang B., Bottinger E.P., Jakowlew S.B., Bagnall K.M., Mariano J., Anver M.R., et al. Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med 4 (1998) 802-807
53. Lutgens E., Gijbels M., Smook M., Heeringa P., Gotwals P., Koteliansky V.E., et al. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol 22 (2002) 975-982
54. Gojova A., Brun V., Esposito B., Cottrez F., Gourdy P., Ardouin P., et al. Specific abrogation of transforming growth factor-{beta} signaling in T cells alters atherosclerotic lesion size and composition in mice. Blood (2003)
55. Robertson A.K., Rudling M., Zhou X., Gorelik L., Flavell R.A., and Hansson G.K. Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest 112 (2003) 1342-1350
56. ten Dijke P., and Hill C.S. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 29 (2004) 265-273
57. Shi Y., and Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113 (2003) 685-700
58. Moustakas A., and Heldin C.H. Non-Smad TGF-beta signals. J Cell Sci 118 (2005) 3573-3584
59. McCaffrey T.A., Consigli S., Du B., Falcone D.J., Sanborn T.A., Spokojny A.M., et al. Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1. J Clin Invest 96 (1995) 2667-2675
60. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J., et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268 (1995) 1336-1338
61. McCaffrey T.A., Du B., Consigli S., Szabo P., Bray P.J., Hartner L., et al. Genomic instability in the type II TGF-beta1 receptor gene in atherosclerotic and restenotic vascular cells. J Clin Invest 100 (1997) 2182-2188
62. Clark K.J., Cary N.R., Grace A.A., and Metcalfe J.C. Microsatellite mutation of type II transforming growth factor-beta receptor is rare in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 21 (2001) 555-559
63. Evanko S.P., Raines E.W., Ross R., Gold L.I., and Wight T.N. Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-beta. Am J Pathol 152 (1998) 533-546
64. Li C.G., Bethell H., Wilson P.B., Bhatnagar D., Walker M.G., and Kumar S. The significance of CD105, TGFbeta and CD105/TGFbeta complexes in coronary artery disease. Atherosclerosis 152 (2000) 249-256
65. Kalinina N., Agrotis A., Antropova Y., Ilyinskaya O., Smirnov V., Tararak E., et al. Smad expression in human atherosclerotic lesions: evidence for impaired TGF-beta/Smad signaling in smooth muscle cells of fibrofatty lesions. Arterioscler Thromb Vasc Biol 24 (2004) 1391-1396
66. McAllister K.A., Grogg K.M., Johnson D.W., Gallione C.J., Baldwin M.A., Jackson C.E., et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8 (1994) 345-351
67. Oshima M., Oshima H., and Taketo M.M. TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol 179 (1996) 297-302
68. Loeys B.L., Schwarze U., Holm T., Callewaert B.L., Thomas G.H., Pannu H., et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 355 (2006) 788-798
69. Disabella E., Grasso M., Marziliano N., Ansaldi S., Lucchelli C., Porcu E., et al. Two novel and one known mutation of the TGFBR2 gene in Marfan syndrome not associated with FBN1 gene defects. Eur J Hum Genet 14 (2006) 34-38
70. Singh K.K., Rommel K., Mishra A., Karck M., Haverich A., Schmidtke J., et al. TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys-Dietz syndrome. Hum Mutat 27 (2006) 770-777
71. Dietz H.C., Cutting G.R., Pyeritz R.E., Maslen C.L., Sakai L.Y., Corson G.M., et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 352 (1991) 337-339
72. Lee B., Godfrey M., Vitale E., Hori H., Mattei M.G., Sarfarazi M., et al. Linkage of Marfan syndrome and a phenotypically related disorder to two different fibrillin genes. Nature 352 (1991) 330-334
73. Maslen C.L., Corson G.M., Maddox B.K., Glanville R.W., and Sakai L.Y. Partial sequence of a candidate gene for the Marfan syndrome. Nature 352 (1991) 334-337
74. Saharinen J., Hyytiainen M., Taipale J., and Keski-Oja J. Latent transforming growth factor-beta binding proteins (LTBPs)-structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev 10 (1999) 99-117
75. Nataatmadja M., West J., and West M. Overexpression of transforming growth factor-beta is associated with increased hyaluronan content and impairment of repair in Marfan syndrome aortic aneurysm. Circulation 114 (2006) I371-I377
76. Rudarakanchana N., Flanagan J.A., Chen H., Upton P.D., Machado R., Patel D., et al. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet 11 (2002) 1517-1525
77. Newman J.H., Trembath R.C., Morse J.A., Grunig E., Loyd J.E., Adnot S., et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol 43 (2004) 33S-39S
78. Stavnezer J. Regulation of antibody production and class switching by TGF-beta. J Immunol 155 (1995) 1647-1651
79. Zhang K. Accessibility control and machinery of immunoglobulin class switch recombination. J Leukoc Biol 73 (2003) 323-332
80. Kovanen P.T., Manttari M., Palosuo T., Manninen V., and Aho K. Prediction of myocardial infarction in dyslipidemic men by elevated levels of immunoglobulin classes A, E, and G, but not M. Arch Intern Med 158 (1998) 1434-1439
81. Mosedale D.E., Chauhan A., Schofield P.M., and Grainger D.J. A pattern of anti-carbohydrate antibody responses present in patients with advanced atherosclerosis. J Immunol Methods 309 (2006) 182-191
82. Mosedale D.E., Smith D.J., Aitken S., Schofield P.M., Clarke S.C., McNab D., et al. Circulating levels of MCP-1 and eotaxin are not associated with presence of atherosclerosis or previous myocardial infarction. Atherosclerosis 183 (2005) 268-274
83. Baidya S.G., and Zeng Q.T. Helper T cells and atherosclerosis: the cytokine web. Postgrad Med J 81 (2005) 746-752
84. Robertson A.K., and Hansson G.K. T cells in atherogenesis: for better or for worse?. Arterioscler Thromb Vasc Biol 26 (2006) 2421-2432
85. Li D., Liu Y., Chen J., Velchala N., Amani F., Nemarkommula A., et al. Suppression of atherogenesis by delivery of TGFbeta1ACT using adeno-associated virus type 2 in LDLR knockout mice. Biochem Biophys Res Commun 344 (2006) 701-707
86. Koglin J., Glysing-Jensen T., Raisanen-Sokolowski A., and Russell M.E. Immune sources of transforming growth factor-beta1 reduce transplant arteriosclerosis: insight derived from a knockout mouse model. Circ Res 83 (1998) 652-660
87. Nabel E.G., Shum L., Pompili V.J., Yang Z.Y., San H., Shu H.B., et al. Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci U S A 90 (1993) 10759-10763
88. Grainger D.J., and Metcalfe J.C. Tamoxifen: teaching an old drug new tricks?. Nat Med 2 (1996) 381-385
89. Grainger D.J., Weissberg P.L., and Metcalfe J.C. Tamoxifen decreases the rate of proliferation of rat vascular smooth-muscle cells in culture by inducing production of transforming growth factor beta. Biochem J 294 Pt 1 (1993) 109-112
90. Grainger D.J., Kirschenlohr H.L., Metcalfe J.C., Weissberg P.L., Wade D.P., and Lawn R.M. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 260 (1993) 1655-1658
91. Grainger D.J., Witchell C.M., and Metcalfe J.C. Tamoxifen elevates transforming growth factor-beta and suppresses diet-induced formation of lipid lesions in mouse aorta. Nat Med 1 (1995) 1067-1073
92. Lawn R.M., Pearle A.D., Kunz L.L., Rubin E.M., Reckless J., Metcalfe J.C., et al. Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice. J Biol Chem 271 (1996) 31367-31371
93. Reckless J., Metcalfe J.C., and Grainger D.J. Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. Circulation 95 (1997) 1542-1548
94. Clarke S.C., Schofield P.M., Grace A.A., Metcalfe J.C., and Kirschenlohr H.L. Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis. Circulation 103 (2001) 1497-1502
95. Elloso M.M., Azrolan N., Sehgal S.N., Hsu P.L., Phiel K.L., Kopec C.A., et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant 3 (2003) 562-569
96. Porreca E., Di Febbo C., di Castelnuovo A., Baccante G., Amore C., Angelini A., et al. Association of factor VII levels with inflammatory parameters in hypercholesterolemic patients. Atherosclerosis 165 (2002) 159-166
97. Youssef S., Stuve O., Patarroyo J.C., Ruiz P.J., Radosevich J.L., Hur E.M., et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420 (2002) 78-84
98. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol Sci 23 (2002) 482-486
99. Grainger D.J., and Schofield P.M. Tamoxifen for the prevention of myocardial infarction in humans: preclinical and early clinical evidence. Circulation 112 (2005) 3018-3024
100. Grainger D.J., Mosedale D.E., Metcalfe J.C., Weissberg P.L., and Kemp P.R. Active and acid-activatable TGF-beta in human sera, platelets and plasma. Clin Chim Acta 235 (1995) 11-31
101. Kropf J., Schurek J.O., Wollner A., and Gressner A.M. Immunological measurement of transforming growth factor-beta 1 (TGF-beta1) in blood; assay development and comparison. Clin Chem 43 (1997) 1965-1974
102. Stefoni S., Cianciolo G., Donati G., Dormi A., Silvestri M.G., Coli L., et al. Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int 61 (2002) 324-335